Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
23.90
+0.24 (1.01%)
At close: Sep 4, 2026, 4:00 PM EDT
24.61
+0.71 (2.97%)
After-hours: Sep 4, 2026, 5:20 PM EDT
Company Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor.
The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jan 31, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 354 |
| CEO | Todd Watanabe |
Contact Details
Address: 3027 Townsgate Road, Suite 300 Westlake Village, California 91361 United States | |
| Phone | 805 418 5006 |
| Website | arcutis.com |
Stock Details
| Ticker Symbol | ARQT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1787306 |
| CUSIP Number | 03969K108 |
| ISIN Number | US03969K1088 |
| Employer ID | 81-2974255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd Franklin Watanabe M.A. | President, Chief Executive Officer and Director |
| Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder and Director Emeritus |
| Latha Vairavan | Senior Vice President and Chief Financial Officer |
| Masaru Matsuda Esq., J.D. | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Patrick E. Burnett M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 27, 2026 | 144 | Filing |
| Aug 20, 2026 | 144 | Filing |
| Aug 19, 2026 | 144 | Filing |
| Aug 17, 2026 | 144 | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | 144 | Filing |
| Aug 7, 2026 | SCHEDULE 13G | Filing |
| Aug 5, 2026 | 10-Q | Quarterly Report |
| Aug 5, 2026 | 8-K | Current Report |
| Aug 3, 2026 | 144 | Filing |